Mr. Stephen Kilmer reports
PROFOUND MEDICAL ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS VOTING RESULTS
Profound Medical Corp. has released the voting results from its annual general and special meeting of shareholders, which was held today. A total of 20,587,011 common shares, representing 68.5 per cent of the common shares outstanding, were represented in person and by proxy at the meeting.
All of the matters put forward before the shareholders, as set out in the company's management information circular dated April 4, 2025, were approved by the requisite majority of votes cast at the meeting.
Election of directors
At the meeting, the shareholders of the company elected all six nominees for the board of directors. Detailed results of the voting in respect of the election of directors are provided in the attached table.
Other matters
The company's shareholders also approved the appointment of PricewaterhouseCoopers LLP as the auditor for the company to hold office until the close of the next annual meeting or until its successor is duly appointed, at such remuneration as may be determined by the board of directors, and an ordinary resolution approving all unallocated options under the company's share option plan, as more particularly described in the information circular. Detailed voting results for all resolutions will be posted under the company's profile on SEDAR+.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing Tulsa-Pro, a technology that combines real-time MRI (magnetic resonance imaging), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The Tulsa procedure, performed using the Tulsa-Pro system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate- or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also to patients requiring salvage therapy for radio-recurrent localized prostate cancer. Tulsa employs real-time MR (magnetic resonance) guidance for precision to preserve patients' urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55 C to 57 C. Tulsa is an incision- and radiation-free one-and-done procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively and efficiently treated with Tulsa. There is no bleeding associated with the procedure; no hospital stay is required; and most Tulsa patients report quick recovery to their normal routine. Tulsa-Pro is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).
Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a humanitarian device exemption for the treatment of osteoid osteoma. The company is in the early stages of exploring additional potential treatment markets for Sonalleve, where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
We seek Safe Harbor.
© 2025 Canjex Publishing Ltd. All rights reserved.